Maratha Headlines

Dry Age-Related Macular Degeneration Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Dry Age-Related Macular Degeneration Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

September 20
22:18 2022
Dry Age-Related Macular Degeneration Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Dry Age-Related Macular Degeneration Market
DelveInsight’s “Dry AMD Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Dry AMD, historical and forecasted epidemiology as well as the Dry AMD market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Dry AMD Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Dry AMD, historical and forecasted epidemiology as well as the Dry AMD market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the Key Facts of the Dry Age-Related Macular Degeneration Market Report:

1 As per Korb et al. (2014), early AMD (stages 1–3) was present in 3.8 % of individuals in the youngest age group (35–44 years); stage 1b, 3.2 %; stage 2a, 0.1 %; stage 2b, 0 % ; stage 3, 0.1), whereas late AMD (stages 4a and 4b) did not appear in the youngest age group.

2 As per Sivaprasad et al. (2019), around 63–75% of patients reported a significant impact on their daily activity tasks like household activities, recognizing faces, watching television, and driving.

3 According to Jost et al. (2017), the global prevalence of any AMD was ~8.7%, with the prevalence of early AMD being 8.0% and the prevalence of late AMD being 0.4%.

4 The total diagnosed cases of dry AMD in the US by age distribution were 2,175,435, 3,380,209, 3,495,783, and 2,614,307 cases for the age group 50–59 years, 60–69 years, 70–79 years, and ≥ 80 years in 2021.

5 The total diagnosed cases of dry AMD by stages in the US were 10,499,160, and 1,166,573 cases for early and intermediate dry AMD and advanced (geographic atrophy associated with dry AMD) in 2021.

6 In the EU5 countries, the total diagnosed cases of dry AMD by stages were 14,774,588, and 1,136,507 cases for early and intermediate dry AMD and advanced (geographic atrophy associated with dry AMD) in 2021. Germany accounted for the highest number of cases of moderate-to-severe whereas Spain accounted for the least number of cases of moderate-to-severe in 2021.

Key Benefits of the Dry AMD Market report:

1 The report covers the descriptive overview of Dry AMD, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

2 Comprehensive insight has been provided into the Dry AMD epidemiology and treatment in the 7MM

3 Additionally, an all-inclusive account of both the current and emerging therapies for Dry AMD is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

4 A detailed review of the Dry AMD market; historical and forecasted is included in the report, covering drug outreach in the 7MM

5 The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Dry AMD market

6 In the coming years, the Dry AMD market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market

7 The companies and academics are working to assess challenges and seek opportunities that could influence Dry AMD R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      

8 Major players are involved in developing therapies for Dry AMD. The launch of emerging therapies will significantly impact the Dry AMD market

9 A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Dry AMD 

Got queries? Click here to know more about the Dry Age Macular Degeneration Market Landscape

Dry Age Macular Degeneration  Overview

Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries worldwide, with a profound effect on the quality of life of affected individuals. With the increase in life expectancy bringing growth in the number of reported cases, it adds a significant burden on the health care systems with the expensive current standard of care. It is one of the leading cause of severe vision loss in adults over 60. An individual is more likely to develop AMD if he/she: have a family history of AMD, smokes cigarettes, is white, eats a diet high in saturated fat, overweight, has hypertension (high blood pressure), is over 50 years old. Having heart disease is another risk factor for AMD, as is having high cholesterol levels.

 

Dry AMD is a common eye disorder among people over 50. It causes blurred or reduced central vision, due to thinning of the macula. The macula is the part of the retina responsible for clear vision in your direct line of sight.There are three stages of dry AMD: early stage, intermediate stage, and advanced stage of dry AMD. The advanced stage of dry AMD is also known as “geographic atrophy (GA),” in which the fovea is compromised.GA is a chronic progressive degeneration of the macula, as part of late-stage dry AMD. It is a progressive, irreversible and blinding disease that tends to affect both eyes. Nearly two-thirds geographic atrophy cases are reported in people aged 80 years and above. GA is responsible for ~20% of all cases of legal blindness in the US and 26% of cases in the UK. Patients with another form of advanced AMD called wet AMD can sometimes also have GA before, during, or after they have the wet form of AMD.The two forms of AMD are not mutually exclusive.Dry AMD usually progresses quite slowly; people can live with the condition for years without discomfort or symptoms that suggest they need treatment.The symptoms of dry AMD include trouble seeing in dim light; straight lines start to appear wavy, blurry or missing, fading and/or changes in the appearance of colors.While there are multiple effective treatments available for neovascular (“wet”) AMD, there are currently no approved treatments for dry-AMD and GA. The AREDS study suggested that supplementing the diet of patients with vitamin C, vitamin E, beta-carotene and zinc could significantly reduce the risk of progressing to advanced AMD and sometimes low visual aids and counseling is also helpful. 

 

Dry Age-Related Macular Degeneration Epidemiological Insight

 

1 As per Prevent Blindness, age-related macular degeneration, affects an estimated 1.8 million Americans aged 40 years and older and an additional 7.3 million with large drusen are at substantial risk of developing AMD

2 As per a study by Owen et al.(2012), for the UK, it was found that overall prevalence of late AMD was 2.4% equivalent to 513 000 cases. Prevalence was 4.8% aged ≥65 years, 12.2% aged ≥80 years. 

According to Colijn et al. (2017), prevalence of early AMD increased from 3.5% in those aged 55-59 years to 17.6% in those aged ≥85 years; for late AMD these figures were 0.1% and 9.8%, respectively. By 2040, the number of individuals in Europe with early AMD will range between 14.9 and 21.5 million, and for late AMD between 3.9 and 4.8 million.

3 Based on the research report published by the European Society of Retina Specialists named Retinal disease in Europe, France accounted for the highest pooled prevalence estimate of late AMD 3.3%, closely followed by Italy 3.2%, Germany 2.4%, and Spain 2.3%.

4 According to a Japanese study by Sakurada et al. (2016), the prevalence of GA was 6.6% among elderly Japanese with AMD

 5 The total diagnosed cases of dry AMD by age distribution in the EU5 were 2,503,127, 3,751,059, 4,838,984, and 4,817,925 cases for the age group 50–59 years, 60–69 years, 70–79 years, and ≥80 years in 2021.

6 In Japan, the total diagnosed cases of dry AMD by age distribution were 932,872, 1,568,416, 2,453,506 and 2,395,145 cases for the age group 50–59 years, 60–69 years, 70–79 years, and ≥80 years in 2021. 

 

Dry Age Related Macular Degeneration  Epidemiological Segmentation 

1 Type-specific (Dry-AMD, Wet-AMD) Prevalence of Age-related Macular Degeneration in the 7MM 

2 Age-specific Prevalence of Dry Age-related Macular Degeneration in the

7MM

3 Geographic Atrophy (GA) Cases by Visual Impairment in the 7MM 

4 Stage-specific Prevalence of Dry Age-related Macular Degeneration

5 Total Prevalent cases of Age-related Macular Degeneration in the 7MM 

 

Dry Age Related Macular Degeneration Market Outlook 

The Dry AMD market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dry AMD market trends by analyzing the impact of current Dry AMD therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of Dry AMD market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dry AMD market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Dry AMD market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @ Dry Age Related Macular Degeneration Market Landscape

Dry Age Related macular degeneration  Key Companies

1 Apellis Pharmaceuticals

2 Iveric bio. 

3 Allegro Ophthalmics

4 NGM Biopharmaceuticals

5 Gyroscope Therapeutics

6  CellCure Neurosciences 

 Dry Age Related Macular Degeneration Therapies 

1Pegcetacoplan

2 Zimura

3 Luminate

4 NGM621

5 GT005

6 OpRegen

Table of Contents

1. Key Insights 

2. Report Introduction 

3 Executive Summary of Dry Age Macular Degeneration 

4 Disease Background and Overview

5 Epidemiology and patient population

6 The United States 

7 EU 5

8.Dry Age Macular Degeneration  Emerging Therapies

9. Dry Age Macular Degeneration Market Outlook

10. Market Access and Reimbursement of Therapies

11. Appendix

12.Dry Age Macular Degeneration  Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

Click here to read more about Dry Age Macular Degeneration Market Landscape 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/